Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases

BACKGROUND: Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackaging system...

Descripción completa

Detalles Bibliográficos
Autores principales: Sodré, Sávio Lima, Barbosa, Italo Antunes França, Pacheco, Israel Emiliano, Ferreira, Felipe de Queiroz Tavares, David, Milton Agrizzi, Nascimento, Mauricio Abujamra, Arieta, Carlos Eduardo Leite, Vasconcellos, Jose Paulo Cabral de
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740002/
https://www.ncbi.nlm.nih.gov/pubmed/31510981
http://dx.doi.org/10.1186/s12889-019-7562-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740002/
https://www.ncbi.nlm.nih.gov/pubmed/31510981
http://dx.doi.org/10.1186/s12889-019-7562-y

Ejemplares similares